10,000 men invited to a landmark study to improve early detection of prostate cancer

• Prostate Cancer Research and Nuffield Health launch BEYOND-PSA to improve early detection of clinically significant prostate cancer.
• Aiming to generate real-world evidence on the use of the Stockholm3 test within a UK clinical pathway, drawing on data from up to 10,000 men accessing Nuffield Health’s enhanced prostate cancer screening service.
• Jeremy Clarkson’s prostate cancer was detected using the Stockholm3 test in 2025.
• Men aged 45-74 accessing Nuffield Health’s informed choice enhanced screening programme will be invited to contribute data to the real-world study, with a philanthropic fund supporting equitable access.

London, UK, 10 Sept 2026 – Prostate Cancer Research and Nuffield Health have announced the launch of BEYOND-PSA, a landmark clinical study aimed at generating real-world evidence on the impact of integrating a sophisticated blood test for prostate cancer, Stockholm3, within a UK clinical pathway.

The study, the first of its kind in the UK, will initially be launched alongside a clinical service delivered at Nuffield Health Barbican Medical Centre. It will evaluate how the Stockholm3 blood-based risk assessment test can be integrated into UK clinical pathways. Where clinically indicated, participants will be referred to the NHS or via their private medical insurance for an MRI scan. If they cannot be referred by either of these routes, the participant will be offered a funded MRI scan at Nuffield Health Highgate Hospital. Up to 10,000 men are expected to contribute data to the study.

Prostate cancer remains the second most common cause of cancer death in UK men, accounting for approximately 12,200 deaths every year.[1] Prostate cancer has extremely high one year survival rates (around 100%) if caught early (in stages 1, 2, or 3) falling to 87.6% if detected in stage 4.[2] By the 5-year mark survival rates for stage 4 metastatic disease fall to 50%, as opposed to 100% in stages 1 and 2 and 95% in stage 3.[3]

While the standard PSA test is a common triage tool for screening, it can sometimes be impacted by lifestyle, miss aggressive cancers, or return high results for non-cancerous conditions, leading to unnecessary anxiety and medical interventions. The Stockholm3 test provides a more accurate risk profile by combining protein biomarkers with genetic markers and clinical data.

The Stockholm3 test was used to help diagnose Jeremy Clarkson’s prostate cancer in 2025[4].

New study data published in June 2026 [5] has contributed to growing international interest in how Stockholm3 may complement existing prostate cancer detection pathways. This includes supporting improved risk assessment and reducing unnecessary costly and invasive investigations, like MRIs or biopsies, particularly in men with elevated PSA levels.

Dr Jayne Spink, BEYOND-PSA Chief Investigator and Chief Scientific Officer at Prostate Cancer Research, said: “Early detection is the most effective way to save lives, yet the current testing landscape means too many aggressive cancers are missed or found too late. We know that 14 per cent of all male cancer deaths in the UK are due to prostate cancer, and this figure rises to 22 per cent in Black men.

Men cannot benefit from innovation that sits on a shelf. If we want to know whether Stockholm3 can help detect more cancers earlier in the UK, we must put it to work within real clinical pathways and measure the impact. BEYOND-PSA will provide the scale of evidence needed to understand what this approach could mean for patients, clinicians and the health system.”

Dr Unnati Desai, National Lead for GP Services at Nuffield Health, said: “Nuffield Health is a not-for-profit healthcare organisation and we are proud to work alongside Prostate Cancer Research to lead this critical, in-depth research into prostate cancer testing to improve health outcomes for men. We have the ability and expertise to be the lead partner of the BEYOND-PSA study, facilitated at our Nuffield Health Barbican Medical Centre and Nuffield Health Highgate Hospital, to provide a unique environment where men can access advanced testing for a nominal cost, whilst remaining integrated with NHS pathways if further investigation is required.”

Gabriel Sam-Yorke, 66, a cab driver from Fulham and the first patient to take part in the study, said: “I’ve seen first-hand what prostate cancer can do. I’ve lost friends to it, and it’s something too many men still don’t talk about, especially here in London where we’ve got the chance to do something about it. That’s why I signed up. It was straightforward, and if taking part helps catch cancer earlier and improve testing for other men, it’s worth it. As a Black man, I know my risk is higher, so I feel a responsibility to be part of this. I’d really encourage men across London to get involved in the study, get checked, and talk to the people around you about it – because the more of us that step forward, the more lives we can save.”

Rishi Sunak MP, Prostate Cancer Research Ambassador, said: “Too many men put off getting checked. But prostate cancer is most treatable when it is found early and without symptoms. We need to diagnose earlier and more accurately, identifying aggressive cancers before they spread. BEYOND-PSA is an important step on that journey. I urge eligible men to register, take part, and help generate the evidence we need to save more lives.”

To support equitable access, the Stockholm3 test will be made available through Nuffield Health’s enhanced screening programme at a subsidised cost of £99. Prostate Cancer Research has also established a limited philanthropic fund to support equitable access initiatives associated with the programme, helping reduce barriers to prostate cancer risk assessment for underserved communities.

Research in Europe on more than 12,000 men aged 50 to 74 found the test identified up to 90 per cent of clinically significant prostate cancers[6].

This compared with rates of 42 per cent detected using standard screening methods, which measure prostate-specific antigen (PSA) and assess risk using age-adjusted thresholds.[7]

The study is open to men aged between 45 and 74, with no previous diagnosis of prostate cancer who are registered with an NHS GP surgery and are able to access the London sites.

Funding for BEYOND-PSA has been provided to PCR by one of the charity’s corporate partners, Information Security Forum (ISF).

Steve Durbin, ISF CEO, said: “Prostate cancer touches far too many lives, which is why we’re proud to support BEYOND-PSA and the vital work being led by Prostate Cancer Research. Earlier detection can make all the difference, and through our support and the reach of our global community, we’re helping to raise awareness, encourage participation and support research to improve outcomes for men and their families in the UK and beyond. If we can help more men take action sooner, save lives and spare families from the trauma of dealing with prostate cancer, the impact will extend far beyond our industry.”

For further information on the study and how to take part, visit: www.nuffieldhealth.com/tests-scans/enhanced-prostate-cancer-screening

or call 03452 302 040

[1] Deaths registered in England and Wales – Office for National Statistics [Internet]. [cited 2026 Apr 10]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationsummarytables/2023#data-on-deaths-registered-in-england-and-wales

[2] Prostate cancer incidence statistics | Cancer Research UK [Internet]. [cited 2026 Apr 10]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence

[3] Cancer survival by stage at diagnosis for England (experimental statistics) – Office for National Statistics [Internet]. [cited 2026 Apr 10]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalbystageatdiagnosisforenglandexperimentalstatistics/latest?

[4] https://www.thetimes.com/uk/healthcare/article/jeremy-clarkson-interview-prostate-cancer-diddly-squat-9xbdz0x5g

[5] https://www.acpjournals.org/doi/10.7326/ANNALS-25-04753

[6] https://www.acpjournals.org/doi/10.7326/ANNALS-25-04753

[7] https://www.acpjournals.org/doi/10.7326/ANNALS-25-04753

ENDS

Media Contact:

Jess Farmery, [email protected]

Notes to Editors:

About the BEYOND-PSA Study
The “Biomarker-Enabled Evaluation of Novel Diagnostic Pathways for Prostate Cancer Stratification and Assessment” (BEYOND-PSA) study is sponsored by Prostate Cancer Research. It evaluates how the Stockholm3 test performs in a UK setting where men access testing through private care and are referred into NHS or private pathways for follow-up care.

Participation in the BEYOND-PSA research study is voluntary and separate from access to the clinical testing pathway.

About Nuffield Health

For nearly 70 years Nuffield Health has been a not-for-profit organisation dedicated to building a healthier nation. We are at the forefront of providing high-quality healthcare and fitness support through our network of 35 hospitals and 110 fitness and wellbeing centres.

We work as a team to help people achieve their health and wellbeing ambitions, providing high-quality hospital care and fitness support, and providing free health and wellbeing programmes in local communities that give people the tools they need to live a healthier life. These programmes help people understand and improve their own health, including those living with joint pain and other long-term conditions, including the effects of cancer and its treatment.

About Prostate Cancer Research (PCR)
Prostate Cancer Research is a patient-centric research and information provision charity dedicated to improving and saving the lives of people with prostate cancer. They fund innovative research projects at world-leading institutions, with a specific focus on tackling health inequities, improving treatments, and developing novel drug targets. For more information, please visit: www.pcr.org.uk

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s

main product, Stockholm3, is a clinically and commercially validated blood test for early

detection and screening of aggressive prostate cancer. A3P Biomedical is headquartered in

Stockholm, Sweden.

About Information Security Forum (ISF)

PCR’s corporate partner Information Security Forum (ISF) are invested in raising awareness of prostate cancer and the importance of early diagnosis. PCR and ISF have joined forces to deliver a 2-year partnership which will be focused on raising awareness, empowering ISF members and networks to make informed choices about their health, and campaigning for men’s health in in the cyber security and IT sectors worldwide. As part of the partnership, ISF are providing vital support for the optimisation of early diagnosis and prostate cancer pathways within private and public healthcare.